Strengthening Japan’s drug discovery and medical research ecosystem: AMED’s innovation challenge

Clicks: 6
ID: 338939
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #51 of 54 articles by views in The Journal of Biochemistry

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Japan continues to face challenges in translating life science and medical research into innovative medicines and healthcare technologies. The Japan Agency for Medical Research and Development (AMED), established in 2015, plays a central role in bridging basic research and practical application. To address gaps between research and development stages and to promote practical application of promising technological seeds from academia, AMED adopted five strategic priorities under its Third Mid- to Long-Term Plan (2025-2029). (1) Strengthen coordination across AMED programs to ensure seamless support from basic research to societal implementation. (2) Promote academia-industry collaboration and technology transfer even at early stages of development, including through the AND-E initiative. (3) Support creative, high-impact basic research and further strengthen innovative research by integration of cutting-edge technologies. (4) Advance international research collaboration, multi-regional clinical trials and support for start-ups, with the AMED Global Hub (Boston) serving as a gateway connecting the Japanese drug discovery ecosystem with global partners. (5) Accelerate digital transformation by leveraging AI, quantum technologies and robust research databases. Taking this integrated approach, AMED aims to revitalize Japan's drug discovery ecosystem, nurture globally competitive talent, and build a world-leading innovation ecosystem that translates scientific excellence into tangible benefits for patients and society.
Reference Key
openalex_W7225304029 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hitoshi Nakagama
Are you one of these authors? Claim your profile
Journal The Journal of Biochemistry
Year 2026
DOI
10.1093/jb/mvag078
URL
https://doi.org/10.1093/jb/mvag078
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.